Usana Health Sciences saw its shares fall sharply this week after releasing second-quarter results that missed analysts’ expectations and after announcing a substantial impairment tied to one of its businesses.
Quarterly results and market reaction
The company reported adjusted earnings of $0.07 per share on sales of about $223 million for the quarter. Those figures came in well below consensus analyst forecasts, with adjusted profit per share missing estimates by about $0.50 and revenue roughly $12 million shy of projections. Over the stretch, the stock lost about 30 per cent of its value, while major U.S. indexes gained ground.
Impairment and revised outlook
Alongside the quarterly results, Usana disclosed it would record a $29-million goodwill impairment related to its Hiya business. The company said that, as a consequence of the charge and weaker operating performance, it now expects to report an annual loss of approximately $11 million, a significant downgrade from prior guidance that projected a profit in the range of $20 million to $27 million.
| Metric | Reported / Revised |
|---|---|
| Q2 adjusted earnings per share | $0.07 |
| Q2 revenue | $223 million |
| Goodwill impairment (Hiya) | $29 million |
| Revised full-year net income outlook | ~$11 million loss |
| Revised full-year sales target | $910 million (from $925M–$1.0B) |
Business segments and near-term prospects
Usana said its core nutrition business has shown some stabilizing signs, but the improvement was overshadowed by softer performance in its Hiya and Rise segments. Management reduced its full-year sales expectation to about $910 million, down from a prior range between $925 million and $1 billion. The company warned that the weak quarter and lowered guidance suggest headwinds could persist in the near term.
- Immediate market impact: roughly 30% decline in share price following the report.
- Accounting impact: a $29-million goodwill impairment tied to Hiya.
- Guidance change: full-year profit outlook shifted to an expected loss of about $11 million; sales guidance trimmed to $910 million.
Analysts and investors typically scrutinise both current-period results and forward guidance for signs of sustainability. In Usana’s case, the combination of a notable earnings miss and an impairment charge focused attention on the company’s ability to return to profitable growth.
Market watchers note that a company in Usana’s position may need to demonstrate a clear turnaround in either sales or margins — or both — before sentiment reverses. Until the company shows evidence that its operating performance is recovering, the stock could remain under pressure, particularly given the reduced earnings outlook and the charge to goodwill.
Usana’s report illustrates how operational challenges and accounting adjustments can converge to create a sharp reassessment of value by investors. For stakeholders — from customers and distributors to shareholders — the near-term priorities will be clarity on execution plans for the underperforming segments and progress toward the company’s longer-term targets.
Further details on management’s proposed corrective measures or updated forecasts will be closely watched in subsequent reports and investor communications.
